10-K · February 26, 2026
Aurinia reports continued commercial momentum for LUPKYNIS with 2025 net product sales of $271.3 million (up 25% vs. $216.2M in 2024), materially stronger operating cash flow of $135.7 million (up 206% vs. $44.4M in…
Earnings analysis · 10-Q
AUPH earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Aurinia Pharmaceuticals reported strong Q1 2026 results with total revenue of $77.7 million, which represents a 24% increase year-over-year. Notable growth was driven by robust net product sales of LUPKYNIS at $73.6…
Read full summary
Aurinia Pharmaceuticals reported strong Q1 2026 results with total revenue of $77.7 million, which represents a 24% increase year-over-year. Notable growth was driven by robust net product sales of LUPKYNIS at $73.6 million, up 23% from the prior year, and a significant rise in operating cash flow to $32.6 million. EPS increased substantially to $0.25 from $0.16 in Q1 2025, reflecting improved profitability.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.25
What stood out
-
Robust Revenue Growth
Total revenue reached $77.7 million, up 24% from $62.5 million in Q1 2025.
-
Strong LUPKYNIS Sales
Net product sales of LUPKYNIS were $73.6 million, a 23% increase from $60 million year-over-year.
-
Significant EPS Increase
Diluted EPS rose to $0.25 from $0.16 in Q1 2025.
-
High Gross Margin
Gross margin improved to 92% in Q1 2026, compared to 86% in Q1 2025.
-
Substantial Operating Cash Flow
Operating cash flow surged to $32.6 million, a 2408% increase from $1.3 million in Q1 2025.
-
Positive Net Income Growth
Net income was $34.4 million, up from $23.3 million in Q1 2025.
What to watch
-
High Cash Outflows
Cash outflows from financing activities were $53.7 million, impacting liquidity.
-
Uncertainties in Product Demand
Dependence on LUPKYNIS sales amidst competitive biopharmaceutical landscape.
-
Market Risks from Regulatory Changes
Potential regulatory risks may affect future product sales and operational stability.
Management's outlook
Aurinia reaffirmed its 2026 revenue guidance, estimating $315M to $325M.
Earlier filings 4
10-Q · November 4, 2025
Aurinia reported Q3 revenue of $73,468,000 and GAAP diluted EPS of $0.23, both up materially versus the year-ago quarter. Net product sales drove the beat ($70,627,000 vs $55,503,000 a year ago) while…
10-Q · May 12, 2025
Aurinia delivered a strong Q1 2025 quarter: revenue of $62.465M (up $12.162M or ~24.2% YoY), a swing to operating income of $21.847M (vs. an operating loss of $13.253M in Q1 2024) and diluted EPS of $0.16. Operating…
10-K · February 27, 2025
Aurinia reported strong commercial traction for LUPKYNIS with net product sales of $216.2M in 2024, up 36% from $158.5M in 2023, and positive operating cash flow of $44.4M versus $(33.5)M in 2023. The company finished…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.